These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24962607)

  • 21. Multimodal prevention of first psychotic episode through N-acetyl-l-cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placebo-controlled, parallel-group trial.
    Schmidt SJ; Hurlemann R; Schultz J; Wasserthal S; Kloss C; Maier W; Meyer-Lindenberg A; Hellmich M; Muthesius-Digón A; Pantel T; Wiesner PS; Klosterkötter J; Ruhrmann S;
    Early Interv Psychiatry; 2019 Dec; 13(6):1404-1415. PubMed ID: 30784233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of oxytocin nasal spray on auditory automatic discrimination measured by mismatch negativity.
    Ochiai H; Shiga T; Hoshino H; Horikoshi S; Kanno K; Wada T; Osakabe Y; Miura I; Yabe H
    Psychopharmacology (Berl); 2021 Jul; 238(7):1781-1789. PubMed ID: 33829308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social Cognitive Skills Training for Psychosis With Community-Based Training Exercises: A Randomized Controlled Trial.
    Horan WP; Dolinsky M; Lee J; Kern RS; Hellemann G; Sugar CA; Glynn SM; Green MF
    Schizophr Bull; 2018 Oct; 44(6):1254-1266. PubMed ID: 29300973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of intranasal oxytocin on neurocognition in people with schizophrenia: A randomized controlled trial.
    İmamoğlu A; Stiles BJ; Jarskog LF; Pedersen CA; Elliott T; Penn DL
    J Psychiatr Res; 2024 Mar; 171():95-98. PubMed ID: 38262165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of Remote Cognitive Training Combined With a Mobile App Intervention on Psychosis: Double-Blind Randomized Controlled Trial.
    Fisher M; Etter K; Murray A; Ghiasi N; LaCross K; Ramsay I; Currie A; Fitzpatrick K; Biagianti B; Schlosser D; Loewy R; Vinogradov S
    J Med Internet Res; 2023 Nov; 25():e48634. PubMed ID: 37955951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
    McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
    JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.
    Einfeld SL; Smith E; McGregor IS; Steinbeck K; Taffe J; Rice LJ; Horstead SK; Rogers N; Hodge MA; Guastella AJ
    Am J Med Genet A; 2014 Sep; 164A(9):2232-9. PubMed ID: 24980612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VR-SOAP, a modular virtual reality treatment for improving social activities and participation of young people with psychosis: a study protocol for a single-blind multi-centre randomized controlled trial.
    Meins IA; Muijsson-Bouwman DC; Nijman SA; Greaves-Lord K; Veling W; Pijnenborg GHM; van der Stouwe ECD
    Trials; 2023 Apr; 24(1):278. PubMed ID: 37061694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A quasi-randomized feasibility pilot study of specific treatments to improve emotion recognition and mental-state reasoning impairments in schizophrenia.
    Marsh PJ; Polito V; Singh S; Coltheart M; Langdon R; Harris AW
    BMC Psychiatry; 2016 Oct; 16(1):360. PubMed ID: 27776504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxytocin administration enhances controlled social cognition in patients with schizophrenia.
    Woolley JD; Chuang B; Lam O; Lai W; O'Donovan A; Rankin KP; Mathalon DH; Vinogradov S
    Psychoneuroendocrinology; 2014 Sep; 47():116-25. PubMed ID: 25001961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment.
    Quintana DS; Westlye LT; Rustan ØG; Tesli N; Poppy CL; Smevik H; Tesli M; Røine M; Mahmoud RA; Smerud KT; Djupesland PG; Andreassen OA
    Transl Psychiatry; 2015 Jul; 5(7):e602. PubMed ID: 26171983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.
    Pedersen CA; Gibson CM; Rau SW; Salimi K; Smedley KL; Casey RL; Leserman J; Jarskog LF; Penn DL
    Schizophr Res; 2011 Oct; 132(1):50-3. PubMed ID: 21840177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.
    Quintana DS; Westlye LT; Hope S; Nærland T; Elvsåshagen T; Dørum E; Rustan Ø; Valstad M; Rezvaya L; Lishaugen H; Stensønes E; Yaqub S; Smerud KT; Mahmoud RA; Djupesland PG; Andreassen OA
    Transl Psychiatry; 2017 May; 7(5):e1136. PubMed ID: 28534875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can repeated intranasal oxytocin administration affect reduced neural sensitivity towards expressive faces in autism? A randomized controlled trial.
    Moerkerke M; Daniels N; Van der Donck S; Tibermont L; Tang T; Debbaut E; Bamps A; Prinsen J; Steyaert J; Alaerts K; Boets B
    J Child Psychol Psychiatry; 2023 Nov; 64(11):1583-1595. PubMed ID: 37278339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial.
    Waite F; Černis E; Kabir T; Iredale E; Johns L; Maughan D; Diamond R; Seddon R; Williams N; Yu LM; Freeman D;
    Lancet Psychiatry; 2023 Sep; 10(9):706-718. PubMed ID: 37562423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive behaviour therapy for improving social recovery in psychosis: a report from the ISREP MRC Trial Platform Study (Improving Social Recovery in Early Psychosis).
    Fowler D; Hodgekins J; Painter M; Reilly T; Crane C; Macmillan I; Mugford M; Croudace T; Jones PB
    Psychol Med; 2009 Oct; 39(10):1627-36. PubMed ID: 19335932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of single dose intranasal oxytocin on social cognition in schizophrenia.
    Davis MC; Lee J; Horan WP; Clarke AD; McGee MR; Green MF; Marder SR
    Schizophr Res; 2013 Jul; 147(2-3):393-7. PubMed ID: 23676253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of Cognitive Bias Modification training and oxytocin administration on trust in maternal support: study protocol for a randomized controlled trial.
    Verhees MWFT; Ceulemans E; Bakermans-Kranenburg MJ; van IJzendoorn MH; de Winter S; Bosmans G
    Trials; 2017 Jul; 18(1):326. PubMed ID: 28709470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants.
    O'Donoghue B; Francey SM; Nelson B; Ratheesh A; Allott K; Graham J; Baldwin L; Alvarez-Jimenez M; Thompson A; Fornito A; Polari A; Berk M; Macneil C; Crisp K; Pantelis C; Yuen HP; Harrigan S; McGorry P
    Early Interv Psychiatry; 2019 Aug; 13(4):953-960. PubMed ID: 30024100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.